XML 66 R36.htm IDEA: XBRL DOCUMENT
v3.24.0.1

Revenues (Tables) | 12 Months Ended
--- | ---
Dec. 31, 2023
Revenue from Contract with Customer [Abstract] |
Disaggregation of Revenue by Product and by Geographic Area | Revenues were as follows (in millions):
|  | Year ended December 31, 2023 |  | Year ended December 31, 2022 |  | Year ended December 31, 2021
|  | U.S. |  | ROW |  | Total |  | U.S. |  | ROW |  | Total |  | U.S. |  | ROW |  | Total
Prolia |  | $ | 2,733 |  |  | $ | 1,315 |  |  | $ | 4,048 |  |  | $ | 2,465 |  |  | $ | 1,163 |  |  | $ | 3,628 |  |  | $ | 2,150 |  |  | $ | 1,098 |  |  | $ | 3,248 |
ENBREL |  | 3,650 |  |  | 47 |  |  | 3,697 |  |  | 4,044 |  |  | 73 |  |  | 4,117 |  |  | 4,352 |  |  | 113 |  |  | 4,465 |
Otezla |  | 1,777 |  |  | 411 |  |  | 2,188 |  |  | 1,886 |  |  | 402 |  |  | 2,288 |  |  | 1,804 |  |  | 445 |  |  | 2,249 |
XGEVA |  | 1,527 |  |  | 585 |  |  | 2,112 |  |  | 1,480 |  |  | 534 |  |  | 2,014 |  |  | 1,434 |  |  | 584 |  |  | 2,018 |
Repatha |  | 793 |  |  | 842 |  |  | 1,635 |  |  | 608 |  |  | 688 |  |  | 1,296 |  |  | 557 |  |  | 560 |  |  | 1,117 |
Nplate |  | 996 |  |  | 481 |  |  | 1,477 |  |  | 848 |  |  | 459 |  |  | 1,307 |  |  | 566 |  |  | 461 |  |  | 1,027 |
KYPROLIS |  | 921 |  |  | 482 |  |  | 1,403 |  |  | 850 |  |  | 397 |  |  | 1,247 |  |  | 736 |  |  | 372 |  |  | 1,108 |
Aranesp |  | 452 |  |  | 910 |  |  | 1,362 |  |  | 521 |  |  | 900 |  |  | 1,421 |  |  | 537 |  |  | 943 |  |  | 1,480 |
EVENITY |  | 809 |  |  | 351 |  |  | 1,160 |  |  | 533 |  |  | 254 |  |  | 787 |  |  | 331 |  |  | 199 |  |  | 530 |
Vectibix |  | 461 |  |  | 523 |  |  | 984 |  |  | 396 |  |  | 497 |  |  | 893 |  |  | 347 |  |  | 526 |  |  | 873 |
BLINCYTO |  | 566 |  |  | 295 |  |  | 861 |  |  | 336 |  |  | 247 |  |  | 583 |  |  | 278 |  |  | 194 |  |  | 472 |
TEPEZZA(1) |  | 441 |  |  | 7 |  |  | 448 |  |  | — |  |  | — |  |  | — |  |  | — |  |  | — |  |  | — |
KRYSTEXXA(1) |  | 272 |  |  | — |  |  | 272 |  |  | — |  |  | — |  |  | — |  |  | — |  |  | — |  |  | — |
Other products(2) |  | 3,874 |  |  | 1,389 |  |  | 5,263 |  |  | 3,776 |  |  | 1,444 |  |  | 5,220 |  |  | 4,194 |  |  | 1,516 |  |  | 5,710 |
Total product sales(3) |  | 19,272 |  |  | 7,638 |  |  | 26,910 |  |  | 17,743 |  |  | 7,058 |  |  | 24,801 |  |  | 17,286 |  |  | 7,011 |  |  | 24,297 |
Other revenues |  | 534 |  |  | 746 |  |  | 1,280 |  |  | 852 |  |  | 670 |  |  | 1,522 |  |  | 908 |  |  | 774 |  |  | 1,682 |
Total revenues |  | $ | 19,806 |  |  | $ | 8,384 |  |  | $ | 28,190 |  |  | $ | 18,595 |  |  | $ | 7,728 |  |  | $ | 26,323 |  |  | $ | 18,194 |  |  | $ | 7,785 |  |  | $ | 25,979 |
____________ (1) TEPEZZA and KRYSTEXXA were acquired from the acquisition of Horizon on October 6, 2023, and includes product sales from the acquisition date through December 31, 2023. (2) Consists of product sales of our non-principal products, as well as sales prior to the divestiture of our Bergamo and Gensenta subsidiaries in the second quarter of 2023 and fourth quarter of 2022, respectively. (3) Hedging gains and losses, which are included in product sales, were not material for the years ended December 31, 2023, 2022 and 2021.
Revenues Earned from Major Customers | For the year ended December 31, 2023, on a combined basis, these customers accounted for 79% of total gross revenues as shown in the following table. Certain information with respect to these customers was as follows (dollar amounts in millions):
| Years ended December 31,
| 2023 |  | 2022 |  | 2021
McKesson Corporation: |  |  |  |  |
Gross product sales | $ | 19,035 |  |  | $ | 17,305 |  |  | $ | 15,187 |
% of total gross revenues | 33 | % |  | 35 | % |  | 33 | %
Cencora, Inc. (formerly AmerisourceBergen Corporation): |  |  |  |  |
Gross product sales | $ | 16,625 |  |  | $ | 15,443 |  |  | $ | 14,783 |
% of total gross revenues | 29 | % |  | 31 | % |  | 32 | %
Cardinal Health, Inc.: |  |  |  |  |
Gross product sales | $ | 9,775 |  |  | $ | 8,319 |  |  | $ | 7,681 |
% of total gross revenues | 17 | % |  | 16 | % |  | 17 | %

X
- Definition Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org//1943274/2147479806/606-10-50-5 + Details
Name: | us-gaap_DisaggregationOfRevenueTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_RevenueFromContractWithCustomerAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 21 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482907/825-10-50-21 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 825 -SubTopic 10 -Section 50 -Paragraph 20 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482907/825-10-50-20 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 18 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482861/275-10-50-18 Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 20 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482861/275-10-50-20 Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 16 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482861/275-10-50-16 Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 21 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482861/275-10-50-21 + Details
Name: | us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration